Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany

Published: September 1, 2020

Avicanna Advances its Supply Chain Business with Commercial Exports of CBG And CBD into the United States and Germany

Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its majority owned subsidiary, Santa Marta Golden Hemp S.A.S. (SMGH), the company has completed exports of CBG and CBD isolates into the United States, CBD isolate into Germany and the commencement of a pilot tracking system for the export of its active pharmaceutical ingredient (API) products in partnership with TruTrace Technologies Inc. The Company is also pleased to announce that the Colombian Ministry of Justice and Law has granted SMGH a commercial and industrial cultivation quota for 12,264 THC plants by.

The export and sale of the commercial lot of isolated CBG into the United States was completed in parallel with commercial export of isolated CBD into the United States, as well as a pilot export for R&D purposes of CBD into Germany. The cultivation, extraction and purification of these cannabinoids including the rare cannabinoid, CBG, were all completed through Avicanna’s vertical integration at SMGH and validate the company’s innovation and leadership in natural rare cannabinoid production. The products are part of the Aureus™ product portfolio that now includes feminized seeds and advanced formulations as well as CBD, CBG and THC API products.

“This is another massive accomplishment for our team in Colombia as we enter the largest market in the world for non-psychoactive cannabinoids with our proprietary CBG offering,” said Aras Azadian, Chief Executive Officer of Avicanna, “As the cannabinoid-derived products sector continues to evolve, our Aureus branded portfolio continues to advance in order to cater to the needs of our cosmetics and pharmaceutical partners, which require an innovative, credible, thoroughly-tested, organic, sustainable and economical source of input materials. Additionally, with the support of TruTrace, the Aureus products will be provided with traceability and trackability all the way back to the seed through a secured blockchain system.”

The Colombian Ministry of Justice and Law granted SMGH a supplementary cultivation quota to cultivate 12,264 psychoactive cannabis plants. 11,587 plants will be destined to produce dry flower which will then be used to manufacture psychoactive derivatives for commercial production for export. The remaining 677 plants will be utilized for psychoactive derivatives for the purposes of research and development and pilot production of Avicanna’s RHO Phyto™ branded products in Colombia.

Lucas Nosiglia, President of Avicanna LATAM commented: “This achievement took years of characterization, evaluation and planning which will finally allow Avicanna to produce our THC products and export THC derivatives to our international partners. As one of the only companies permitted to produce THC commercially for the global market, we can focus on less competitive and high margin products.”

To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.

Designed specifically by TruTrace for the cannabis industry, StrainSecure™ is a fully integrated software platform, secured on blockchain which aggregates and authenticates all testing and quality assurance data on products and verifies the quality of each batch and lot in distribution. Furthermore, this deployment will mark the first utilization by TruTrace of the OrionOne™ global freight and logistics solution in the cannabis sector thereby providing dynamic visibility of verified Aureus products through the entire international shipping process.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.